December 17, 2007
Biosynexus Incorporated Repurchase of Pagibaximab From GlaxoSmithKline (GSK)

November 2007
Pagibaximab bulk drug substance was manufactured for Biosynexus by a major pharmaceutical company headquartered in Chicago, Illinois.  

March 2004
Biosynexus successfully completed a Phase 2a trial with 88 enrolled very low birth weight (VLBW) infants drawn from 17 neonatal intensive care units (NICUs) in the United States. The study confirmed safety, linear pharmacokinetics and bactericidal activity in infant serum of the antibody.

June 14, 2005
Biosynexus Incorporated Acquired by QVT Fund LP;
Irwin Scher Named CEO of Biosynexus Incorporated

October 30, 2003
Biosynexus' New Anti-microbial Agent Destroys MRSA Biofilm
Only Compound Shown to be Capable of Eliminating Biofilm and Killing S. aureus
 
October 14, 2003
Biosynexus Announces Successful Completion of Phase I/II Trial for Topical Anti-Staph Cream for Eradication of S. aureus Nasal Colonization
BSYX-L210 Meets Endpoints of Safety and Microbiological Activity
 
October 2, 2002
GlaxoSmithKline Biologicals and Biosynexus Announce
Partnership to Prevent Multi-resistant Bacteria Infection
 
May 14, 2002
Biosynexus Presents Results of
First Clinical Study of an Anti-staphylococcal Monoclonal Antibody